Report from the 19th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Winnipeg, Manitoba; 29–30 September 2017
Christina Kim, A. Zaidi(University of Saskatchewan), Karen Mulder, Bryan Brunet(University of Saskatchewan), Shahid Ahmed(Emory University), Haji Chalchal, Richard M. Lee‐Ying(Alberta Health Services), Bak‐Sau Yip(CancerCare Manitoba), Jonathan M. Loree(University of British Columbia), John Paul McGhie(BC Cancer Agency), Howard J. Lim(BC Cancer Agency), Jason Park(CancerCare Manitoba), David Liu(Bristol-Myers Squibb (Germany)), Ralph Wong(CancerCare Manitoba), Vinessa Gordon(CancerCare Manitoba), R. Deobald(University of Saskatchewan), Marc P. Dupre(CancerCare Manitoba), C. Döll(University of Alberta)
Cited by 1
Related Papers
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
|Journal of Clinical Oncology|2013|775
Obesity and Cancer: A Current Overview of Epidemiology, Pathogenesis, Outcomes, and Management
|Cancers|2023|640